Clinic
Dimensions Health Corporation
Dimensions Health Corporation was paid $29.59M by Medicaid between Jan 2018 and Nov 2024, across 139 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoDIMENSIONS HEALTH CORPORATION
UPPER MARLBORO, MD 20774
UPPER MARLBORO, MD 20774
33aNPI1720099286assigned 08/10/2006
33bProvider typeMedical Specialty Clinic/Center
28Total paid$29.59M
24GClaims288,257
24DCodes billed139
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Medical Specialty Clinic/Center providers in Maryland
Rank by total paid#1 of 23
Median peer was paid$104K
This provider vs. median283×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,951 | $6.59M | |
| 2019 | 61,310 | $6.23M | |
| 2020 | 43,416 | $4.77M | |
| 2021 | 44,295 | $4.11M | |
| 2022 | 38,106 | $3.48M | |
| 2023 | 27,356 | $2.56M | |
| 2024incomplete | 17,823 | $1.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 17,001 | 14,996 | $7.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 19,669 | 17,055 | $5.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 8,316 | 7,297 | $4.67M |
| G0378 | Hospital observation service, per hour | 13% | 4,641 | 3,350 | $3.72M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 8.4% | 23,391 | 19,465 | $2.49M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 2,484 | 2,209 | $433K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 2,636 | 2,381 | $379K |
| 80053 | Comprehensive metabolic panel | 1.2% | 18,036 | 14,716 | $355K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 24,391 | 18,342 | $352K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 3,121 | 2,731 | $324K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 4,942 | 4,489 | $302K |
| 84484 | <1% | 8,015 | 6,155 | $251K |
127 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 6,638 | $221K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,239 | $195K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,486 | $172K |
| 59025 | Fetal non-stress test | <1% | 254 | $156K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 365 | $152K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,933 | $147K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,897 | $140K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,340 | $123K |
| 76801 | <1% | 341 | $118K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,454 | $102K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,989 | $99K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,219 | $98K |
| 73562 | <1% | 911 | $98K | |
| 81001 | <1% | 7,627 | $97K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,340 | $89K |
| 83605 | <1% | 3,510 | $88K | |
| 84702 | <1% | 1,736 | $88K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,130 | $88K |
| 80320 | <1% | 3,059 | $80K | |
| 84703 | <1% | 3,994 | $75K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 791 | $73K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,374 | $73K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 777 | $73K |
| 73130 | <1% | 754 | $72K | |
| 85730 | <1% | 4,179 | $65K | |
| 86803 | <1% | 1,351 | $62K | |
| 83690 | <1% | 5,314 | $61K | |
| 83735 | <1% | 8,708 | $60K | |
| 73610 | <1% | 601 | $53K | |
| 86850 | <1% | 2,550 | $51K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 437 | $51K |
| 87430 | <1% | 858 | $47K | |
| 83880 | <1% | 1,954 | $47K | |
| 73630 | <1% | 568 | $47K | |
| 73030 | <1% | 662 | $46K | |
| 82962 | <1% | 3,705 | $45K | |
| 85610 | <1% | 4,716 | $42K | |
| 70486 | <1% | 696 | $38K | |
| 81025 | <1% | 1,449 | $36K | |
| 81003 | <1% | 5,753 | $36K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 162 | $36K |
| 93971 | <1% | 146 | $35K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 91 | $35K |
| 87070 | <1% | 575 | $32K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 123 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,544 | $26K |
| 86901 | <1% | 2,815 | $25K | |
| 85379 | <1% | 839 | $25K | |
| 72126 | <1% | 219 | $23K | |
| 93970 | <1% | 87 | $23K | |
| 76830 | Ultrasound, transvaginal | <1% | 57 | $21K |
| 90715 | <1% | 225 | $19K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 410 | $18K |
| 86900 | <1% | 2,650 | $18K | |
| 87210 | <1% | 1,062 | $17K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 336 | $16K |
| 72131 | <1% | 230 | $15K | |
| 82550 | <1% | 1,930 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,814 | $14K |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 702 | $12K |
| 72128 | <1% | 182 | $12K | |
| 73110 | <1% | 120 | $11K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 45 | $11K |
| 80061 | Lipid panel | <1% | 639 | $10K |
| 81015 | <1% | 1,212 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 668 | $10K |
| 72100 | <1% | 100 | $9K | |
| 87040 | <1% | 238 | $9K | |
| 84100 | <1% | 3,080 | $9K | |
| 73590 | <1% | 112 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,361 | $8K |
| 72170 | <1% | 89 | $8K | |
| 87081 | <1% | 162 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,089 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 233 | $7K |
| 73502 | <1% | 76 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 160 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,262 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,579 | $5K |
| 97161 | <1% | 29 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,118 | $4K |
| A4649 | Surgical supply; miscellaneous | <1% | 677 | $4K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $4K |
| 72132 | <1% | 44 | $3K | |
| J3490 | Unclassified drugs | <1% | 231 | $3K |
| 80329 | <1% | 137 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,248 | $2K |
| 72129 | <1% | 32 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 182 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 435 | $2K |
| 73090 | <1% | 25 | $2K | |
| 94644 | <1% | 87 | $2K | |
| 97165 | <1% | 14 | $2K | |
| 85384 | <1% | 70 | $2K | |
| 85032 | <1% | 106 | $2K | |
| 82553 | <1% | 104 | $1K | |
| 73552 | <1% | 13 | $1K | |
| A9270 | Non-covered item or service | <1% | 6,139 | $1K |
| 82150 | <1% | 56 | $958.07 | |
| 80076 | <1% | 78 | $878.38 | |
| 87186 | <1% | 90 | $821.69 | |
| 85027 | <1% | 168 | $719.61 | |
| 94760 | <1% | 135 | $675.52 | |
| 74018 | <1% | 16 | $391.83 | |
| 71250 | <1% | 29 | $343.29 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 373 | $338.41 |
| 94010 | <1% | 12 | $289.93 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 124 | $283.07 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 91 | $262.98 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 151 | $259.19 |
| J2704 | Injection, propofol, 10 mg | <1% | 84 | $198.35 |
| 94664 | <1% | 25 | $166.66 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 227 | $159.46 |
| 87077 | <1% | 74 | $152.52 | |
| 87205 | <1% | 13 | $108.01 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 42 | $91.17 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 113 | $77.78 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 424 | $76.67 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 20 | $42.41 |
| 84132 | <1% | 12 | $28.13 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 26 | $21.61 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 23 | $20.89 |
| 0270 | 0% | 563 | $0.00 | |
| 0250 | 0% | 128 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 686 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROZIC, MICHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Dimensions Healthcare Associates INC | Laurel, MD | $2.18M |
| Dimensions Healthcare Associates INC | Laurel, MD | $1.58M |
| Dimensions Healthcare Associates INC | Laurel, MD | $361K |
| Dimensions Health Associates Dba University of Maryland Capital Region | Oxon Hill, MD | $144K |
| Dimensions Healthcare Associates INC | Laurel, MD | $99K |
| Dimensions Health Corporation | Bowie, MD | $4K |
| Dimensions Healthcare Associates | Largo, MD | $328.62 |
| Dimensions Health Corporation | Upper Marlboro, MD | $225.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.